Drugs

, Volume 73, Issue 6, pp 595–604

Pomalidomide: First Global Approval

Authors

    • Adis R & D Insight
  • Paul L. McCormack
    • Adis, Springer Healthcare
R&D Insight Report

DOI: 10.1007/s40265-013-0047-x

Cite this article as:
Elkinson, S. & McCormack, P.L. Drugs (2013) 73: 595. doi:10.1007/s40265-013-0047-x

Abstract

Pomalidomide (Pomalyst®) is a small molecule analogue of thalidomide under development with Celgene Corporation for the oral treatment of haematological and connective tissue diseases. Pomalidomide has been approved in the USA and is awaiting approval in the EU for use with low-dose dexamethasone for the treatment of relapsed and refractory multiple myeloma that has progressed following at least two prior therapies, including lenalidomide and bortezomib. The efficacy and safety of pomalidomide as monotherapy in patients with relapsed and refractory multiple myeloma has also been evaluated in a phase III trial. The agent is in phase III clinical development for the treatment of myelofibrosis and in phase II development for systemic sclerosis. Pomalidomide is also being investigated in patients with amyloidosis, prostate cancer, small cell lung cancer, pancreatic cancer, graft-versus-host disease, and Waldenstrom’s macroglobulinaemia. This article summarizes the milestones in the development of pomalidomide leading to this first global approval for relapsed and refractory multiple myeloma.

Copyright information

© Springer International Publishing Switzerland 2013